[HTML] mdpi.com

[HTML][HTML] Current treatment options for chronic myeloid leukemia patients failing second-generation tyrosine kinase inhibitors

V García-Gutiérrez, JC Hernández-Boluda - Journal of Clinical Medicine, 2020 - mdpi.com
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …
被引用次数：19 相关文章

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors

V García-Gutiérrez, JC Hernández-Boluda - Journal of Clinical Medicine, 2020 - cir.nii.ac.jp
抄録< jats: p> Despite the excellent overall survival (OS) of patients with chronic myeloid
leukemia (CML), a significant proportion will not achieve optimal response to imatinib or …

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors.

V García-Gutiérrez… - Journal of Clinical …, 2020 - europepmc.org
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors

V García-Gutiérrez… - Journal of Clinical …, 2020 - search.proquest.com
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors

V García-Gutiérrez… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors.

V García-Gutiérrez… - Journal of Clinical …, 2020 - search.ebscohost.com
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …
[HTML] nih.gov

[HTML][HTML] Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors

V García-Gutiérrez… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …
[PDF] semanticscholar.org

[PDF][PDF] Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors

V García-Gutiérrez, JC Hernández-Boluda - J. Clin. Med, 2020 - pdfs.semanticscholar.org
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors.

V García-Gutiérrez… - Journal of Clinical …, 2020 - europepmc.org
Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …